Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Most relevant
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ASTELLAS PHARMA INC.
2018Astellas Is Reportedly Considering Selling Europe Assets To Raise Cash
CI
2018ASTELLAS PHARMA : U.S. FDA Approves XTANDI« (enzalutamide) for the Treatment of ..
PU
2018Astellas Pharma Inc. and Pfizer Inc. Receive Approval for Supplemental New Dr..
CI
2018ASTELLAS PHARMA : Received Approval for Dafclir« Tablets for the Treatment of In..
PU
2018ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares
PU
2018Tranche Update on Astellas Pharma Inc.'s Equity Buyback Plan announced on May..
CI
2018Astellas Pharma Inc. Receives Approval for Dafclir Tablets for the Treatment ..
CI
2018ASTELLAS PHARMA : Results from Pivotal Phase 3 PROSPER Trial of XTANDI« (enzalut..
PU
2018Astellas Pharma Inc. Announces Results from Pivotal Phase 3 PROSPER Trial of ..
CI
2018ASTELLAS PHARMA : Named to FTSE4Good Index Series for the Seventh Consecutive Ye..
PU
2018ASTELLAS PHARMA : Announces Launch of XTANDI« Tablets in Japan for the Treatment..
PU
2018ASTELLAS PHARMA : and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedoti..
PU
2018ASTELLAS PHARMA : Announces Personnel Change
PU
2018ASTELLAS PHARMA : Oncology C3 Prize« Returns for Third Year with Focus on Improv..
PU
2018ASTELLAS PHARMA : and FibroGen Announce Topline Results from Double-Blind Japan ..
PU
2018ASTELLAS PHARMA : Submits Application for Approval of Peficitinib for Rheumatoid..
PU
2018ASTELLAS PHARMA : Announces Acquisition of Own Shares
PU
2018Astellas Pharma Inc. and Fibrogen Announce Topline Results from Double-Blind ..
CI
2018Astellas Pharma Inc. announces an Equity Buyback for 60,000,000 shares, repre..
CI
2018Astellas Pharma Inc. Submits Application for Approval of Peficitinib for Rheu..
CI
2018Astellas Pharma Inc. authorizes a Buyback Plan.
CI
2018ASTELLAS PHARMA : U.S. FDA Grants Priority Review to Astellas' New Drug Applicat..
PU
2018Astellas Pharma Inc. announces U.S. FDA Grants Priority Review to Astellas' N..
CI
2018Eurofins Pharma Services Lux Holding SARL signed an agreement to acquire Aste..
CI
2018Astellas Pharma Inc. Announces Restructuring of Operations in Japan
CI
2018Astellas Pharma Inc. Appoints Bernhardt Zeiher, as New Chief Medical Officer
CI
2018Astellas Pharma Inc. Announces FDA Approves Supplemental New Drug Application..
CI
2018Iota Biosciences, Inc. announced a financing transaction
CI
2018Astellas Pharma Seeks Acquisitions on Specific Areas
CI
2018ASTELLAS PHARMA : Reports Financial Results for FY2017
BU
2018Astellas Pharma Inc. Reports Consolidated Earnings Results for the Fiscal Yea..
CI
2018Astellas Submits New Drug Applications for Approval of Gilteritinib for the T..
CI
2018Proteostasis Therapeutics, Inc. and Astellas Pharma Inc. Enters into Amendmen..
CI
2018Kite Pharma, Inc. acquired Certain Agensys Research Facilities of Astellas Ph..
CI
2018Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate fro..
CI
2018Astellas Announces Executive Changes
CI
2018Actinium Pharmaceuticals, Inc. Announces Collaborative Research Partnership w..
CI
2018ASTELLAS PHARMA INC : Ex-dividend day for final dividend
FA
2018Tranche Update on Astellas Pharma Inc.'s Equity Buyback Plan announced on Jan..
CI
2018MSD K.K. and Astellas Pharma Inc. Announce MSD's Marketing Approval of SUJANU..
CI
2018Astellas Pharma Inc.'s Equity Buyback announced on January 31, 2018 has expir..
CI
2018Pfizer Inc. and Astellas Pharma Inc. Announces Supplemental New Drug Applicat..
CI
2018Astellas Promotes Roderick Christmon to New Executive Director, Medical & Dev..
CI
2018Astellas Pharma Inc. Receives Approval for Solifenacin Oral Suspension for Pe..
CI
2018Astellas Pharma Inc. Enters into Licensing Agreement with Tottori University ..
CI
2018Astellas Receives Approval for Xtandi Tablets,A Treatment for Castration-Resi..
CI
2018ASTELLAS PHARMA : Launches Global Campaign in Collaboration with CNN as Part of ..
PU
2018Astellas Pharma Inc. acquired Universal Cells Inc. for JPY 8,130 million.
CI
2018ASTELLAS PHARMA : Acquires Universal Cells, Inc. (pdf 178KB)
PU
2018ASTELLAS PHARMA : Partners with Discovery Communications for its Global Branding..
PU
2018ASTELLAS PHARMA : Announce Top-Line Results for Two Phase 3 Trials of Peficitini..
PU
2018Astellas Announce Top-Line Results for Two Phase 3 Trials of Peficitinib in R..
CI
2018Astellas Pharma Inc. and Pfizer Inc. Announces Results from the Phase 3 Prosp..
CI
2018ASTELLAS PHARMA : Announces Changes in Management Structure, Global Function, an..
PU
2018ASTELLAS PHARMA : Announces Personnel Changes and Organizational Changes (pdf 30..
PU
2018Astellas Pharma Inc. Announces Board Changes; Effective Date from April 1, 20..
CI
2018Astellas Pharma Inc. authorizes a Buyback Plan.
CI
2018Astellas Pharma Inc. announces an Equity Buyback for 42,000,000 shares, repre..
CI
2018ASTELLAS PHARMA : Announces Transition to a Company with an Audit & Supervisory ..
PU
2018ASTELLAS PHARMA : Announces Acquisition of Own Shares (pdf 119KB)
PU
2018ASTELLAS PHARMA : Reports Financial Results for the First Nine Months of FY2017 ..
PU
2018ASTELLAS PHARMA : Reports Financial Results for the First Nine Months of FY2017
BU
2018Astellas Pharma Inc. Reports Consolidated Financial Results for the Third Qua..
CI
2018Astellas Pharma Inc. Announces Dividend Forecast for the Year 2017
CI
2018ASTELLAS PHARMA : Completes Acquisition of Mitobridge, Inc. (pdf 242KB)
PU
2018Astellas Pharma Inc. completed the acquisition of remaining 73.6% stake in Mi..
CI
2018ASTELLAS PHARMA : Receives Orphan Designation from the European Commission for G..
PU
2018ASTELLAS PHARMA : and Vical Announce Top-Line Results for Phase 3 Trial of Cytom..
PU
2018Astellas Pharma Inc. and Vical Incorporated Announce Top-Line Results for Pha..
CI
2018ASTELLAS PHARMA : Repatha« SC Injection 420 mg Auto Mini Doser Launched in Japan..
PU
2018Amgen Astellas Biopharma K.K. and Astellas Pharma Inc. Announce Launch of Rep..
CI
2018ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..
PU
2018Astellas Pharma Inc. and Kotobuki Pharmaceutical Co., Ltd. Submit Supplementa..
CI
2018ASTELLAS PHARMA : Application for Marketing Approval Submitted for Bispecific CD..
PU
2017ASTELLAS PHARMA : to Present at J.P. Morgan Healthcare Conference (pdf 178KB)
PU
Prev.1  2  3  4  5   6  7  8  9  10Next
Upcoming event on ASTELLAS PHARMA INC.
09/29/21